UBS

Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.

A Cepheid executive today provided investors with an update on the company's molecular diagnostic pipeline, stating that the firm currently has 14 tests in development for its automated GeneXpert platform and that it expects to offer the broadest test menu of any molecular diagno

Several mass spec vendors presented this week at the UBS Global Life Sciences Conference in New York City, offering information on various aspects of their businesses, including portions of their proteomics portfolios.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The UBS Global Life Sciences Conference concluded on Wednesday with presentations in the afternoon by GenturaDx and Epigenomics.

Speaking at the UBS Global Life Sciences conference in New York on Monday, Bio-Rad Laboratories President and CEO Norman Schwartz told attendees that Bio-Rad planned to launch the platform to test for sexually transmitted diseases.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.